Zolbetuximab in the treatment of advanced gastric and gastroesophageal junction cancer: a systematic review - Top-Institutions - MDSpire

Zolbetuximab in the treatment of advanced gastric and gastroesophageal junction cancer: a systematic review

  • By

  • Natalia Picheta

  • Julia Piekarz

  • Jakub Pobideł

  • Katarzyna Szklener

  • Magdalena Skórzewska

  • July 16, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Princess Margaret Cancer Centre
    Princess Margaret Cancer Centre

    Toronto, Ontario

    Key Differentiators

    • Oncology

  • #2

    our hospital
    our hospital

    Unknown, Unknown

    Key Differentiators

    • General Healthcare

  • #3

    Yonsei University College of Medicine
    Yonsei University College of Medicine

    Seoul, South Korea

    Key Differentiators

    • Oncology

  • #4

    Songdang Institute for Cancer Research
    Songdang Institute for Cancer Research

    Seoul, South Korea

    Key Differentiators

    • Oncology

Original Source(s)

Zolbetuximab in the treatment of advanced gastric and gastroesophageal junction cancer: a systematic review

  • by Natalia Picheta, Julia Piekarz, Jakub Pobideł, Katarzyna Szklener, Magdalena Skórzewska

  • July 16, 2026

Related Content

Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis

Immune checkpoint crosstalk: CTLA-4/CD80 engagement as a predictor of anti-PD-1/PD-L1 therapy outcome in NSCLC

Serum M2BPGi as a predictor of hepatocellular carcinoma development in chronic hepatitis B and C: a systematic review and meta-analysis